Genmab’s stock experienced a decline following the results of a Phase 3 trial for their drug epcoritamab. The trial failed to meet a key endpoint, causing concern among investors. This setback may impact the company’s future prospects and development pipeline. The stock price fell as a result of the disappointing news.

Read more at Investing.com: Genmab stock falls after Phase 3 epcoritamab trial misses key endpoint